Table 1 Analysis of associations between clinicopathologic factors and effect of neoadjuvant chemotherapy
Variable | All, n (%) | pCR, n (%) | Non-pCR, n (%) | P value |
|---|---|---|---|---|
Patient age (years) | 48.7 ± 10.7 | 45.0 ± 10.4 | 49.9 ± 10.6 | 0.169 |
Tumor size (mm3)* | 11.6 ± 11.2 | 11.7 ± 11.7 | 11.3 ± 10.1 | 0.936 |
Histological type* | ||||
Invasive | 47 (94.0) | 11 (91.7) | 36 (94.7) | |
Other | 3 (6.0) | 1 (8.3) | 2 (5.3) | 0.696 |
Histologic grade* | ||||
1–2 | 34 (68.0) | 11 (91.7) | 23 (60.5) | |
3 | 16 (32.0) | 1 (8.3) | 15 (24.0) | 0.060 |
Clinical stage* | ||||
II | 18 (36.0) | 9 (75.0) | 9 (76.0) | |
III | 32 (64.0) | 3 (25.0) | 29 (71.0) | 0.001 |
T stage* | ||||
T1–T2 | 19 (38.0) | 9 (75.0) | 10 (26.3) | |
T3–T4 | 31 (62.0) | 3 (25.0) | 28 (73.7) | 0.002 |
N stage* | ||||
N0 | 4 (8.0) | 1 (8.3) | 3 (7.9) | |
N1–3 | 46 (92.0) | 11 (91.7) | 35 (92.1) | 0.961 |
Lymph node size* | ||||
≤ 1.0 cm | 29 (58.0) | 7 (58.3) | 22 (57.9) | |
> 1.0 cm | 21 (42.0) | 5 (41.7) | 16 (42.1) | 0.979 |
NAC regimen | ||||
EC | 16 (32.0) | 4 (33.3) | 12 (31.6) | |
EC-T(H) | 24 (48.0) | 6 (50.0) | 18 (47.4) | |
TEC or other | 10 (20.0) | 2 (16.7) | 8 (21.1) | 0.947 |
AC cycle | ||||
1–4 | 16 (32.0) | 3 (25.0) | 13 (34.2) | |
5–8 | 34 (68.0) | 9 (75.0) | 25 (65.8) | 0.551 |
CEA level* | ||||
Normal | 45 (90.0) | 11 (91.7) | 34 (89.5) | |
Abnormal | 5 (10.0) | 1 (8.3) | 4 (10.5) | 0.654 |
CA125 level* | ||||
Normal | 46 (92.0) | 11 (91.7) | 35 (92.1) | |
Abnormal | 4 (8.0) | 1 (8.3) | 3 (7.9) | 0.961 |
CA153 level* | ||||
Normal | 45 (90.0) | 10 (83.3) | 35 (92.1) | |
Abnormal | 5 (10.0) | 2 (16.7) | 3 (7.9) | 0.377 |
Breast cancer subtype | ||||
TNBC | 12 (24.0) | 4 (33.3) | 8 (21.1) | |
Her-2 positive | 10 (20.0) | 2 (16.7) | 8 (21.1) | |
Luminal A(B) | 28 (56.0) | 6 (50.0) | 22 (57.9) | 0.683 |
Ki-67 status | ||||
≤ 20% | 15 (30.0) | 2 (16.7) | 13 (34.2) | |
> 20% | 35 (70.0) | 10 (83.3) | 25 (65.8) | 0.248 |